CVN293 was generally well-tolerated in healthy volunteers with evidence of robust brain penetration, supporting utility of KCNK13 inhibitors for ...

Cerevance’s attempt to unlock the first-line Parkinson's disease market has hit a snag, with solengepras performing no better ...

The ASCEND trial evaluated the safety, tolerability, and efficacy of solengepras and aimed to establish its potential to ...

The pivotal, Phase III study will evaluate the change in average daily “OFF” time in solengepras patients compared to placebo ...

At the recent AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s Disease (PD), Cerevance announced that solengepras, a first-in-class G-protein coupled receptor 6 (GPR6) antagonist in ...

Cerevance has said it plans to move on to late-stage trials of its first-in-class Parkinson's disease drug CVN424 after hitting the mark in a phase 2 proof-of-concept study. The Boston-based ...

Solengepras, the most advanced investigational treatment in Cerevance's pipeline, is an oral, non-dopaminergic therapy in Phase 3 development for Parkinson's disease. A brain-penetrant, specific ...

UK-based clinical-stage biopharmaceutical company Cerevance has announced top-line results from the Phase II ASCEND trial of solengepras as an investigational monotherapy in patients with early, ...

Takeda and venture capital group Lightstone Ventures have launched Cerevance, a neuroscience company focused on discovering and developing novel therapeutics for neurological and psychiatric ...